Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma

The use of high dose chemotherapy followed by autologous peripheral blood stem cell (PBSC)
transplantation in recurrent nasopharyngeal carcinoma has shown promise when compared with
standard chemotherapy. This study has been designed to evaluate response rates and
toxicities associated with undergoing high dose conditioning with Etoposide, Carboplatin and
Ifosfamide followed by autologous stem cell transplantation support in the treatment of
recurrent nasopharyngeal carcinoma in children, adolescents, and young adults.

Inclusion Criteria:

- Imaging and tissue diagnosis of recurrent or progressive nasopharyngeal carcinoma

- Documentation of previous treatment including conventional chemotherapy and/or
radiation therapy as clinically appropriate

- Ages 2 to 30 years of age

- Negative serum pregnancy test if applicable

- Calculated creatinine clearance of greater than 60 mL/minute, serum creatinine of
less than 12o micromoles/L, total bilirubin less than 2 mg/dL and aspartate
aminotransferase (AST) must be less than twice the upper limit of normal

Exclusion Criteria:

- Unsuitable candidate for autologous transplantation due to comorbidities or
intractable psychosocial issues

- Pregnancy

- Breast-feeding women